Efficacy of Pancrelipase on Postprandial Belching and Bloating.
Phase 3
Completed
- Conditions
- Postprandial BloatingPostprandial BelchingPostprandial Eructation
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2005-12-19
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT00266721
- Locations
- 🇺🇸
VAMC, Minneapolis, Minnesota, United States
Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)
Phase 3
Completed
- Conditions
- Knee Osteoarthritis
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2008-02-20
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00264225
- Locations
- 🇫🇷
Site 3, Andernos Les Bains, France
🇫🇷Site 105, Angers, France
🇫🇷Site 101, Angers, France
Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
Phase 3
Completed
- Conditions
- Postmenopause
- Interventions
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2008-03-12
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 391
- Registration Number
- NCT00251082
- Locations
- 🇵🇱
Site 33, Kraków, Poland
🇫🇷Site 23, Cannes, France
🇫🇷Site 21, Montpellier, France
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
Phase 2
Completed
- Conditions
- Endometriosis
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00244452
- Locations
- 🇷🇴
Site 4007, Bucuresti, Romania
🇷🇴Site 4005, Bucuresti, Romania
🇺🇦Site 3803, Kiev, Ukraine
Patient-reported Outcomes in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00230828
Pharmacokinetic Evaluation of Testosterone Gel (1%)
Phase 1
Completed
- Conditions
- Primary or Secondary HypogonadismConstitutional Delay in Growth and Puberty (CDGP)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-12-25
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00193700
- Locations
- 🇺🇸
Site 209, Cincinnati, Ohio, United States
🇺🇸Site 205, Seattle, Washington, United States
🇺🇸Site 207, Brooklyn, New York, United States
Bifeprunox in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00193713
Bifeprunox in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 986
- Registration Number
- NCT00193687
Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
Phase 2
Completed
- Conditions
- Primary or Secondary HypogonadismConstitutional Delay in Growth and Puberty (CDGP)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00193661
- Locations
- 🇺🇸
Site 125, Philadelphia, Pennsylvania, United States
🇺🇸Site 126, Philadelphia, Pennsylvania, United States
🇺🇸Site 111, Kansas City, Missouri, United States
Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00160186
- Locations
- 🇸🇪
Site 6, Stockholm, Sweden
🇫🇮Site 10, Tampere, Finland
🇩🇰Site 9, Odense, Denmark
© Copyright 2025. All Rights Reserved by MedPath